Catalytic hydrogenation of unactivated amides enabled by hydrogenation of catalyst precursor
摘要:
A general method for catalytic hydrogenation of unactivated amides was achieved. During the catalyst induction period, a novel structural change was observed involving full hydrogenation of the interior unsaturated bonds of the pyridines of the Ru-containing catalyst precursor. Based on this observation, the mechanism of amide hydrogenation may involve a two-step pathway, wherein the Ru catalyst having an H-Ru-N-H functionality is generated in the first step, followed by the amide carbonyl group interacting with the outer, rather than the inner, sphere of the Ru catalyst. (c) 2013 Elsevier Ltd. All rights reserved.
PHARMACOLOGICALLY ACTIVE OCTAHYDRO-PYRIDO(1,2-a) PYRAZINES
申请人:AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.
公开号:EP0257072A1
公开(公告)日:1988-03-02
NOVEL COMPOUNDS
申请人:SMITHKLINE BEECHAM PLC
公开号:EP1066288A2
公开(公告)日:2001-01-10
[EN] PHARMACOLOGICALLY ACTIVE OCTAHYDRO-PYRIDO(1,2-a) PYRAZINES
申请人:AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.
公开号:WO1987005022A2
公开(公告)日:1987-08-27
(EN) Pharmacologically active compound of formula (III), and pharmaceutically acceptable acid addition salts thereof. The process for preparing the compound (III) involves the use as a new intermediate of 2-(N-3-trifluoromethylphenylaminomethyl)-piperidine (II). Pharmaceutical formulations containing the compound of formula (III) or an acid addition salt thereof.(FR) Composé pharmacologiquement actif de formule (III) et ses sels d'addition d'acide pharmaceutiquement acceptables. Le procédé de préparation du composé (III) comporte l'utilisation, en tant que nouvel intermédiaire, de 2-(N-3-trifluorométhylphénylaminométhyl)-pipéridine (II). Sont également décrites des composition pharmaceutiques contenant le composé de formule (III) ou un de ses sels d'addition d'acide.
[EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
申请人:——
公开号:WO1999042465A2
公开(公告)日:1999-08-26
[EN] Novel sulphonamide derivatives having CNS activity, processes for their preparation and their use as medicaments. [FR] Nouveaux dérivés de sulfamide dont l'activité permet de traiter des maladies du système nerveux central, leurs procédés de préparation et leur utilisation en tant que médicaments.